← Leaderboards
Michael Edward Hagensee
Louisiana State Univ Hsc New Orleans
$4,706,892
Attributed
$7,630,780
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $814.2K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,630,780 · 10
By mechanism
R01$6,394,425 · 3
R21$417,600 · 1
R03$361,724 · 3
U54$268,989 · 1
M01$188,042 · 2
Top collaborators
- Paul L Fidel5 shared
- Ann L. Griffen5 shared
- Eugene J Leys5 shared
- Jennifer Erin Cameron2 shared
- Craig M Meyers2 shared
Most similar at Louisiana State Univ Hsc New Orleans
Same institution · by research overlap
- Paul L Fidel$10,381,300
- Elizabeth T. Fontham$512,666
- Janet E Leigh$432,385
Others in their field
Top investigators on “Human Papillomavirus”
- Ronald T Mitsuyasu · University Of California Los Angeles$106,431,894
- Leonard Freedman · Leidos Biomedical Research, Inc.$53,948,093
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$50,130,116
- Paula Gonzalez-Maya · Fundacion Inciensa$38,145,031
- David Heimbrook · Leidos Biomedical Research, Inc.$33,306,253
- Paul F Lambert · University Of Wisconsin Madison$31,091,618
Research focus
Human PapillomavirusClinical ResearchInfectionReportingPreventSamplingLesionRisk FactorsLeadHigh RiskBiopsyMalignant Neoplasm Of Cervix UteriMalignant NeoplasmsOncogenicVirusPathologyAntiretroviral TherapyAnti-Retroviral AgentsTissuesVirus DiseasesCellsEpidemiologySiteHiv Infections
Grant awards (26)
The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection$638,067
R01 · FY2025 · DE
The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection$637,738
R01 · FY2024 · DE
Project 1$142,471
U54 · FY2024 · CA · contact PI
Project 1$126,518
U54 · FY2023 · CA · contact PI
The Oral Microbiome in HIV-associated Oral Warts and Candidiasis$541,240
R01 · FY2017 · DE
The Oral Microbiome in HIV-associated Oral Warts and Candidiasis$597,308
R01 · FY2016 · DE
The Oral Microbiome in HIV-associated Oral Warts and Candidiasis$566,416
R01 · FY2015 · DE
The Oral Microbiome in HIV-associated Oral Warts and Candidiasis$554,339
R01 · FY2014 · DE
The Oral Microbiome in HIV-associated Oral Warts and Candidiasis$505,165
R01 · FY2013 · DE
Interaction of EBV and HPV in the Development of Cervical Dysplasia in HIV+ Women$351,669
R01 · FY2012 · CA · contact PI
Interaction of EBV and HPV in the Development of Cervical Dysplasia in HIV+ Women$391,877
R01 · FY2011 · CA · contact PI
Interaction of EBV and HPV in the Development of Cervical Dysplasia in HIV+ Women$376,477
R01 · FY2010 · CA · contact PI
Interaction of EBV and HPV in the development of cervical dysplasia in HIV+ women$443,635
R01 · FY2009 · CA · contact PI
Interaction of EBV and HPV in the Development of Cervical Dysplasia in HIV+ Women$370,529
R01 · FY2009 · CA · contact PI
Interaction of EBV and HPV in the Development of Cervical Dysplasia in HIV+ Women$419,965
R01 · FY2008 · CA · contact PI
ORAL HPV INFECTION IN HIV CO-INFECTED INDIVIDUALS$62,862
M01 · FY2006 · RR · contact PI
Development of immune assays for HPV-32$14,850
R03 · FY2006 · CA · contact PI
ORAL HPV INFECTION IN HIV CO-INFECTED INDIVIDUALS$77,526
M01 · FY2005 · RR
Development of immune assays for HPV-32$71,000
R03 · FY2005 · CA
Development of immune assays for HPV-32$69,740
R03 · FY2004 · CA
ORAL HPV INFECTION IN HIV CO-INFECTED INDIVIDUALS$47,654
M01 · FY2004 · RR
Prevalence of HPV in the Oral Cavity of HIV+ Individuals$210,900
R21 · FY2003 · DE
Prevalence of HPV in the Oral Cavity of HIV+ Individuals$206,700
R21 · FY2002 · DE
DEVELOPMENT OF A URINE PCR ASSAY FOR HPV DNA DETECTION$71,500
R03 · FY2001 · CA
DEVELOPMENT OF A URINE PCR ASSAY FOR HPV DNA DETECTION$69,350
R03 · FY2000 · CA
NONINVASIVE DETECTION OF ANTIBODIES AGAINST HPV$65,284
R03 · FY2000 · CA